Danny Glover ‘Acting’ as Spokesman for Anemia LifeLine

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 5
Volume 11
Issue 5

NEW YORK-Actor Danny Glover is serving as spokesman for Anemia LifeLine, a new educational initiative. Mr. Glover’s father had anemia associated with chronic kidney disease. At a press conference to launch the initiative, Mr. Glover told how anemia had robbed his father James Glover of his desire to do the things he loved. He said his father was ready to give up, but treatment gave him back his energy and independence.

NEW YORK—Actor Danny Glover is serving as spokesman for Anemia LifeLine, a new educational initiative. Mr. Glover’s father had anemia associated with chronic kidney disease. At a press conference to launch the initiative, Mr. Glover told how anemia had robbed his father James Glover of his desire to do the things he loved. He said his father was ready to give up, but treatment gave him back his energy and independence.

Anemia LifeLine was developed by Amgen Inc. in collaboration with the National Kidney Foundation; The Wellness Community, a national support group for cancer patients; and the National Anemia Action Council, representing various clinical specialties.

The campaign was designed to increase awareness of the signs and symptoms of anemia associated with serious disease, provide educational materials, encourage people to seek treatment, and demonstrate that treatment can lead to a healthier, more productive life.

Mr. Glover will make appearances throughout the country at National Kidney Foundation Kidney Walks and at anemia awareness events at malls. He will be featured in public service announcements and in educational materials available via a toll-free line (1-888-722-4407) and on the web (www.anemia.com). 

Recent Videos
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
3 experts are featured in this series.
3 experts are featured in this series.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
4 experts are featured in this series.
6 experts are featured in this series.
Related Content